影像学直径-厚度比对HER2阳性可切除进展期胃癌患者长期生存及分期迁移的价值
研究回顾性纳入369例HER2阳性可切除进展期胃癌患者,以影像学直径-厚度比4.0为界分组,DT比<4.0组总生存58.0个月 vs DT比≥4.0组31.0个月,无进展生存43.0个月 vs 24.0个月。DT比是独立预后因素,pStage II且DT比≥4.0患者预后与pStage III且DT比<4.0患者相似(OS P=0.418,PFS P=0.867)。
要点
- DT比<4.0组总生存58.0个月、无进展生存43.0个月,均长于DT比≥4.0组的31.0个月和24.0个月。
- DT比是独立预后因素,可识别N0和II期患者中的高危亚群。
- pStage II且DT比≥4.0患者预后与pStage III且DT比<4.0患者相似,提示存在分期迁移效应。
核心结论
- 影像学DT比可评估HER2阳性可切除进展期胃癌患者预后并识别更高恶性病例。
- DT比可能指导临床医生制定术后策略。
研究设计与样本
- 回顾性纳入369例HER2阳性可切除进展期胃癌患者,收集临床病理特征、影像学DT比及结局(OS和PFS)。
- 采用Pearson卡方检验和Student t检验比较基线特征,Kaplan-Meier分析和Log-rank检验估计临床结局。
- 采用单因素和多因素Cox回归模型分析独立预后因素。
诊断标准与关键数值
- 以DT比截断值4.0将患者分为两组(P<0.05)。
- DT比<4.0组OS 58.0个月 vs DT比≥4.0组31.0个月。
- DT比<4.0组PFS 43.0个月 vs DT比≥4.0组24.0个月。
- DT比对N0和II期患者预后有显著预测价值(P<0.05)。
- 胃体和胃窦癌患者在DT比<4.0组中OS和PFS更长(P=0.046、0.017、0.036和0.028)。
临床应用与阅片要点
- DT比≥4.0的pStage II患者预后与DT比<4.0的pStage III患者相似(OS P=0.418,PFS P=0.867)。
- 作者认为DT比可能指导临床医生制定术后策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the clinical significance and stage migration effect of radiological diameter-to-thickness (DT) ratio in HER2-positive resectable advanced gastric cancer (HER2-p RAGC).
METHODS: 369 HER2-p RAGC patients were retrospectively enrolled and information on clinical pathological characteristics, radiological DT ratio, and outcomes [i.e., overall survival (OS) and progression-free survival (PFS)] was collected. Pearson's Chi-square and Student's t-test were employed to compare baseline characteristics. Clinical outcomes were estimated using Kaplan-Meier analysis and Log-rank test. Univariate and multivariate Cox regression models were utilized to analyze independent prognostic factors.
RESULTS: HER2-p RAGC patients were stratified into two groups using a DT ratio cutoff value of 4.0 (p < 0.05). Patients with a DT ratio < 4.0 exhibited significantly longer OS (58.0 vs. 31.0 months) and PFS (43.0 vs. 24.0 months) than those with a DT ratio ≥ 4.0. DT ratio significantly predicted prognosis for N0 and II stage patients (p < 0.05). Patients with gastric body and antrum cancers demonstrated longer OS and PFS in the DT ratio < 4.0 group (p = 0.046, 0.017, 0.036 and 0.028). Multivariate Cox proportional hazard model identified age, pathological T category, pathological N category, pathological TNM category and DT ratio as independent prognostic factors. Notably, pStage II patients with a DT ratio ≥ 4.0 exhibited a similar prognosis to pStage III patients with a DT ratio < 4.0 (p = 0.418 for OS, 0.867 for PFS).
CONCLUSION: Radiological DT ratio could evaluate the prognosis and detect higher malignant cases in HER2-p RAGC patients. Moreover, DT ratio might guide clinicians make postoperative strategies.
TRIAL REGISTRATION: Retrospectively registered.
引用
- Hou B, Guo T, Gao J, et al. The value of the radiological diameter-to-thickness ratio in patients with HER2-positive resectable advanced gastric cancer: implications for long survival and stage migration. Abdom Radiol (NY). 2024. PMID: 38907839. doi:10.1007/s00261-024-04420-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。